Drug Trial Radar · NCT06789913
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
277
Planned (sponsor's estimate)
Start
Jun 13, 2025
Primary completion
Jul 2031
Study completion Oct 2031
Sponsor
- Lead sponsor
- Relay Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.
Conditions
- PIK3CA-Related Overgrowth Spectrum (PROS)
- Lymphatic Malformations
- Vascular Malformations
- PIK3CA Mutation
- CLOVES Syndrome
- Klippel Trenaunay Syndrome
- Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
- Vascular Anomalies
Interventions
RLY-2608Drug
RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
PlaceboDrug
RLY-2608 matched-placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1 and 2: Determination of a recommended phase 2 dose RP2D(s) for Groups 1, 2, and 3Time frame: Cycle 1 of treatment and at the end of every cycle until study discontinuation
- Parts 1 and 2: Occurrence/frequency of Adverse Events (AEs), changes in vital signs, ECGs, and safety laboratory tests and their relationship to the study drugs (safety and tolerability).Time frame: Cycle 1 of treatment and at the end of every cycle until study discontinuation
- Part 3: Percentage of participants with volumetric Response.Time frame: Baseline, Week 24
Locations
49 sites in 10 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
University of California, Los Angeles
Los Angeles, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Children's Hospital of Atlanta
Atlanta, Georgia · Recruiting
Riley Children's Hospital
Indianapolis, Indiana · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Johns Hopkins Medical Institute
Baltimore, Maryland · Recruiting
Boston Children's Hospital
Boston, Massachusetts · Recruiting
Corewell Health
Grand Rapids, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
University of Missouri
Columbia, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
NYU Langone Health
New York, New York · Recruiting
UNC Chapel Hill
Chapel Hill, North Carolina · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
Cleveland Clinic Children's
Cleveland, Ohio · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Texas Children's Hospital
Houston, Texas · Recruiting
University of Texas Health Center - Houston
Houston, Texas · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
University of Wisconsin, Madison
Madison, Wisconsin · Recruiting
The Skin Hospital
Sydney, Australia · Recruiting
Sydney Children's Hospital at Westmead
Westmead, Australia · Recruiting
Sydney Children's Hospital, Randwick
Randwick, New South Wales, Australia · Recruiting
Children's Health Queensland Hospital and Health
South Brisbane, Queensland, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
Royal Melbourne Hospital
Parkville, Victoria, Australia · Recruiting
Murdoch Children's Research Institute
Parkville, Victoria, Australia · Recruiting
UC Louvain
Brussels, Belgium · Recruiting
CHU Amiens
Amiens, France · Recruiting
CHU de Bordeaux
Bordeaux, France · Recruiting
CHU Dijon
Dijon, France · Recruiting
Hôpital de la Timone
Marseille, France · Recruiting
Necker Hospital
Paris, France · Recruiting
University of Halle
Halle, Germany · Recruiting
Children's Health Ireland at Crumlin
Dublin, Ireland · Recruiting
Ospedale Maggiore Policlinico
Milan, Italy · Recruiting
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.